130 related articles for article (PubMed ID: 17053813)
1. The effects of FasL on inflammation and tumor survival are dependent on its expression levels.
Wada A; Tada Y; Kawamura K; Takiguchi Y; Tatsumi K; Kuriyama T; Takenouchi T; O-Wang J; Tagawa M
Cancer Gene Ther; 2007 Mar; 14(3):262-7. PubMed ID: 17053813
[TBL] [Abstract][Full Text] [Related]
2. T cell dependent and independent antitumor immunity generated by the expression of Fas ligand on mouse lung carcinoma cells.
Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Int J Mol Med; 2002 Mar; 9(3):281-5. PubMed ID: 11836634
[TBL] [Abstract][Full Text] [Related]
3. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects are produced by forced expression of membrane-bound but not soluble Fas ligand in murine lung carcinoma cells.
Tada Y; O-Wang J; Seimiya M; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Anticancer Res; 2002; 22(2A):831-6. PubMed ID: 12014659
[TBL] [Abstract][Full Text] [Related]
5. Fas ligand-expressing tumors induce tumor-specific protective immunity in the inoculated hosts but vaccination with the apoptotic tumors suppresses antitumor immunity.
Tada Y; O-Wang J; Wada A; Takiguchi Y; Tatsumi K; Kuriyama T; Sakiyama S; Tagawa M
Cancer Gene Ther; 2003 Feb; 10(2):134-40. PubMed ID: 12536202
[TBL] [Abstract][Full Text] [Related]
6. Expression of FasL by tumor cells does not abrogate anti-tumor CTL function.
Lee SH; Bar-Haim E; Goldberger O; Reich-Zeliger S; Vadai E; Tzehoval E; Eisenbach L
Immunol Lett; 2004 Feb; 91(2-3):119-26. PubMed ID: 15019279
[TBL] [Abstract][Full Text] [Related]
7. Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo.
Yoshimoto Y; Kawada M; Ikeda D; Ishizuka M
Int Immunopharmacol; 2005 Feb; 5(2):281-8. PubMed ID: 15652759
[TBL] [Abstract][Full Text] [Related]
8. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
Ryan AE; Shanahan F; O'Connell J; Houston AM
Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
[TBL] [Abstract][Full Text] [Related]
9. Vaccination of apoptotic Fas ligand-expressing tumors decreased antitumor responses by enhanced production of immunosuppressive cytokines.
Wada A; Tada Y; Shimozato O; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Anticancer Res; 2005; 25(1A):299-303. PubMed ID: 15816551
[TBL] [Abstract][Full Text] [Related]
10. In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells.
Grangeon C; Cormary C; Douin-Echinard V; Favre G; Couderc B; Tilkin-Mariamé AF
Cancer Gene Ther; 2002 Mar; 9(3):282-8. PubMed ID: 11896445
[TBL] [Abstract][Full Text] [Related]
11. Direct in vivo transfection of antisense Fas-ligand reduces tumor growth and invasion.
Nyhus JK; Wolford C; Feng L; Barbera-Guillem E
Gene Ther; 2001 Feb; 8(3):209-14. PubMed ID: 11313792
[TBL] [Abstract][Full Text] [Related]
12. CM101 treatment overrides tumor-induced immunoprivilege leading to apoptosis.
Yakes FM; Wamil BD; Sun F; Yan HP; Carter CE; Hellerqvist CG
Cancer Res; 2000 Oct; 60(20):5740-6. PubMed ID: 11059768
[TBL] [Abstract][Full Text] [Related]
13. Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation.
Dupont PJ; Warrens AN
Immunology; 2007 Jan; 120(1):133-9. PubMed ID: 17233740
[TBL] [Abstract][Full Text] [Related]
14. A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells.
Savai R; Schermuly RT; Pullamsetti SS; Schneider M; Greschus S; Ghofrani HA; Traupe H; Grimminger F; Banat GA
Cancer Res; 2007 Jun; 67(11):5443-53. PubMed ID: 17545626
[TBL] [Abstract][Full Text] [Related]
15. The influence of CD95L expression on tumor rejection in mice.
Igney FH; Behrens CK; Krammer PH
Eur J Immunol; 2003 Oct; 33(10):2811-21. PubMed ID: 14515265
[TBL] [Abstract][Full Text] [Related]
16. Control of ocular tumor growth and metastatic spread by soluble and membrane Fas ligand.
Gregory MS; Saff RR; Marshak-Rothstein A; Ksander BR
Cancer Res; 2007 Dec; 67(24):11951-8. PubMed ID: 18089826
[TBL] [Abstract][Full Text] [Related]
17. Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity.
Shimizu M; Fontana A; Takeda Y; Yoshimoto T; Tsubura A; Matsuzawa A
Cell Immunol; 2001 Jan; 207(1):41-8. PubMed ID: 11161452
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD40 ligand in CD40-positive murine tumors activates transcription of the interleukin-23 subunit genes and produces antitumor responses.
Wada A; Tada Y; Shimozato O; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Anticancer Res; 2004; 24(5A):2713-6. PubMed ID: 15517876
[TBL] [Abstract][Full Text] [Related]
19. A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege.
Gregory MS; Koh S; Huang E; Saff RR; Marshak-Rothstein A; Mukai S; Ksander BR
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2495-502. PubMed ID: 15980241
[TBL] [Abstract][Full Text] [Related]
20. Cutting edge: a novel role for Fas ligand in facilitating antigen acquisition by dendritic cells.
Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Okada S; Tokuhisa T; Sakiyama S; Tagawa M
J Immunol; 2002 Sep; 169(5):2241-5. PubMed ID: 12193688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
